Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Opinion & Analysis (NDAQ:CELG)

    Why the election is not as relevant to drug stocks as you might believe

    The Life Sciences Report November 4, 2016

    Diffusion Pharmaceuticals takes aim at brain cancer: CEO David Kalergis

    The Life Sciences Report April 1, 2016

    Circling the globe for uncommon biotech opportunities

    The Life Sciences Report February 18, 2016

    Biotech Bears Spark Good Vibes For These ETFs

    Benzinga.com  October 6, 2015

    BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

    Gail Dutton October 1, 2015

    CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

    Gail Dutton September 10, 2015

    Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

    George S. Mack September 3, 2015

    The Other Bearish Biotech ETF Is Looking Groovy, Too

    Benzinga.com  August 21, 2015

    An undervalued biotech is testing the cure for cancer now, and Chen Lin wants in

    Peter Byrne June 3, 2015

    3 Biotech ETFs Rally On Merger News

    Benzinga.com  December 8, 2014

    A Look At 3 Overbought ETFs

    Benzinga.com  December 2, 2014

    Biotechnology, Oil And Brazil ETFs To Watch This Week

    Benzinga.com  September 2, 2014

    Biotechs Struggling To Find A Bottom

    Benzinga.com  April 8, 2014

    Did the government shutdown help the economy?

    Frank Holmes  December 12, 2013

    Big Pharma has a big problem and merger mania is heating up

    Marc Lichtenfeld July 29, 2010

    A low-risk double no matter which way this stock moves

    Rob Fannon December 7, 2009